• Phenothiazines Enhance Macrophage Antibacterial Activity

  2026-08-27

  A 2025 Frontiers in Immunology study identifies phenothiazines as host-directed antibacterial candidates that strengthen macrophage activity through coordinated lysosomal activation, autophagy, and reactive oxygen species accumulation. Perphenazine also reduced Salmonella Typhimurium-associated tissue lesions and inflammation in vivo, although the work does not establish a dopamine D2-dependent mechanism or clinical efficacy.

• Temafloxacin BA1108: Reliable Assay Workflows

  2026-08-26

  Temafloxacin (SKU BA1108) supports carefully controlled antibacterial, infection-model, and intracellular assay workflows when concentration, solvent, and host-cell controls are handled explicitly. This scenario-based guide explains how to select concentrations, interpret viability data, prepare solutions, and evaluate product reliability without confusing antibacterial activity with mammalian cytotoxicity.

• TAK-715 Workflow for p38 MAPK Research

  2026-08-26

  TAK-715 combines nanomolar p38α-directed activity with a useful framework for separating kinase blockade from downstream cytokine effects. This article translates that profile into cell-based, biochemical, and inflammation-model workflows, with practical controls for solvent handling, phospho-signaling interpretation, and assay optimization.

• Vasopressin Analogues: Evidence and Applications

  2026-08-25

  Glavaš and colleagues provide a literature-based framework linking vasopressin structure, receptor pharmacology, proteolytic stability, and therapeutic use across natural, synthetic, and non-peptide analogues. The review positions lypressin, desmopressin, and terlipressin as examples of how targeted molecular changes can shift peptides toward antidiuretic, vasoconstrictive, hemostatic, or investigational antiviral activity.

• NHE1, Octanal/Olfr2, and Atherosclerosis

  2026-08-25

  A 2025 Scientific Reports study identifies macrophage NHE1 as a downstream mediator of octanal/Olfr2-driven atherosclerosis, connecting this signaling axis with calcium-dependent ROS production and NLRP3 inflammasome activation. Using ApoE−/− mice and RAW264.7 macrophages, the work combines genetic, pharmacological, and calcium-chelation approaches to define a potential intervention point in vascular inflammation.

• hCG, EZH2, and CXCL10 in Decidual Immune Regulation

  2026-08-24

  The reference study shows that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal cells by directing EZH2-dependent H3K27me3 deposition to a defined CXCL10 promoter region. This links an embryonic trophoblast signal to chromatin remodeling in maternal tissue and provides a mechanistic explanation for reduced CD8 T-cell recruitment at the maternal–fetal interface.

• Autophagy, Lipid Breakdown, and Lipotoxicity in Salmon

  2026-08-23

  A 2025 study shows that rapamycin-induced autophagy promotes lipid-droplet breakdown and reduces lipotoxic stress in Atlantic salmon SHK-1 cells. By combining lipidomics and proteomics, the researchers connect autophagy activation with unsaturated triacylglycerol storage and changes in lipid-associated proteins, providing a mechanistic cell model relevant to fish health research.

• NLRP10, Keratinocyte Survival, and AD Barrier Function

  2026-08-22

  This 2024 study defines NLRP10 as an epidermal homeostasis regulator rather than simply an inflammasome-associated protein. Using human atopic dermatitis samples and air-lift human skin equivalents, the authors connect NLRP10 to caspase-8-dependent keratinocyte survival, p63 stabilization, epidermal differentiation, and barrier integrity.

• Dihydroethidium for Superoxide Assays in ALI

  2026-08-21

  Learn how to apply Dihydroethidium (DHE), or hydroethidine, to live-cell superoxide measurement in acute lung injury and ferroptosis models. This practical guide combines assay setup, controls, workflow optimization, and troubleshooting with mechanistic insight from recent Nrf2/GPX4 research.

• Adefovir Dipivoxil in Chronic Hepatitis B

  2026-08-21

  The reference review established adefovir dipivoxil as a clinically useful nucleotide analog for chronic hepatitis B, emphasizing activity against both wild-type and lamivudine-resistant HBV. Its central translational insight links prodrug activation, selective HBV polymerase inhibition, durable viral suppression, and a comparatively low resistance rate to long-term treatment strategies.

• TMEM16F in Kupffer Cells Protects Against Listeria

  2026-08-20

  The 2024 Advanced Science study identifies Kupffer cell-expressed TMEM16F as a key determinant of host protection during Listeria monocytogenes infection. By linking calcium-activated lipid scrambling and plasma-membrane repair to liver inflammation, tissue injury, and metabolic regulation, the work refines how cell-type-specific membrane defense shapes systemic antibacterial immunity.

• SOD Activity Assay Kit: From Signal to Biology

  2026-08-20

  The Superoxide Dismutase Activity Assay Kit measures enzyme function through inhibition of WST-1 formazan formation. This guide explains the assay mechanism, interprets an important ROS-measurement caveat, and shows how to design more defensible oxidative stress experiments.

• Anlotinib Hydrochloride: Assay Logic for Angiogenesis

  2026-08-19

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose activity is best understood by connecting receptor phosphorylation to endothelial phenotypes. This assay-centered guide explains how to interpret migration, tube formation, tissue sprouting, pharmacokinetics, and translational limits in cancer research.

• Measuring Growth Inhibition and Cell Death in Cancer

  2026-08-19

  Hannah R. Schwartz’s dissertation examines a central problem in cancer pharmacology: relative viability and fractional viability are often treated as interchangeable even though they capture different biological outcomes. Its key contribution is a framework for separating proliferation arrest from cell killing, enabling more precise interpretation of in vitro drug responses and better alignment between assay design and biological questions.

• Bacitracin (B1670): Practical Research Guide

  2026-08-18

  Bacitracin (B1670) provides a peptide antibiotic reagent for controlled antibacterial research focused on bacterial cell wall and peptidoglycan synthesis disruption. It is intended for in vitro scientific workflows only, not for diagnostic, therapeutic, or other medical use.

457 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page